Triple Target Treatment (3T) Which Combines Stimulation With Amplitude Modulated Middle Frequency (AM-MF), Electromyography (EMG)-Triggered Stimulation and EMG-Biofeedback Compared With EMG-Biofeedback in Anal Incontinence (3T-AI)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00525291|
Recruitment Status : Completed
First Posted : September 5, 2007
Last Update Posted : February 18, 2009
The efficacy of biofeedback and/or low frequency electrical stimulation for the treatment of anal incontinence has not been proven. First, large well-designed clinical trials are missing. Second, only few patients reach therapeutically relevant intensities with low frequency stimulation. In this study, a novel therapeutic concept, termed triple target treatment (3T) was evaluated. 3T combines stimulation with amplitude modulated middle frequency (AM-MF), electromyography (EMG)-triggered stimulation and EMG-biofeedback. 3T was compared with EMG-biofeedback alone after a nine month treatment period.
Methods In this parallel-group randomised multicenter study with blinded observer we enrolled 158 patients with anal incontinence. Primary endpoints were changes from baseline to nine months in the Cleveland Clinic Score (CCS) and the St. Mark's score (Vaizey score).
|Condition or disease||Intervention/treatment||Phase|
|Fecal Incontinence||Device: Combination of EMG-biofeedback plus EMG-triggered AM-MF-stimulation Device: EMG-biofeedback alone||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||158 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||Prospective, Randomized Multicenter Study to Assess the Outcome of Conservative 3T Treatment With EMG-Biofeedback|
|Study Start Date :||July 2007|
|Actual Primary Completion Date :||December 2008|
|Actual Study Completion Date :||December 2008|
|Experimental: EMG-biofeedback plus EMG-triggered AM-MF-stimulation||
Device: Combination of EMG-biofeedback plus EMG-triggered AM-MF-stimulation
In the 3T arm, patients were stimulated with a carrier wave of 25 KHz and biphasic modulations of the pulse train of 40 Hz. Anxious patients trained at first only in the biofeedback mode. The stimulation was introduced after four weeks for these patients. Patients were instructed to carry out the training at home, with an alternating combination in the morning and with EMG-triggered stimulation in the evening, each for 20-minute periods. Apart from this, the protocol of the active treatment group was identical to that of the control group.
|Active Comparator: EMG-biofeedback alone||
Device: EMG-biofeedback alone
In the biofeedback arm, patients were instructed to carry out EMG-biofeedback training at home, standing, mornings and evenings, for 20-minute periods. The core of the task was to pull the plug-electrode upward inside the anal channel, like a lift, and to hold it there during varying periods of tension. This can only be done successfully if the perineum rises and at the same time the puborectal muscle is activated. Just squeezing the sphincter muscles does not produce this lifting effect.
- Cleveland Clinic Incontinence Score (CCS) in its validated German form after nine months, compared to baseline [ Time Frame: 9 months after randomization ]
- Validated new St. Mark's incontinence score (Vaizey score) in its adapted German form after nine months, compared to baseline. [ Time Frame: 9 months after randomization ]
- CCS score after six or three months, compared to baseline [ Time Frame: 3 months, 6 months after randomization ]
- Adapted Vaizey score after six or three months compared to baseline [ Time Frame: 3 months, 6 months ]
- Quality of life according to the Fecal Incontinence Quality of Life Scale (FIQoL) in its validated German form after nine months compared to baseline, as well as between the two treatment groups over the course of time as compared to baseline [ Time Frame: 9 months after randomization ]
- Track record of the treatment: 1. Continent, 2. Grade improvement (grade II or III to grade I), 3. Frequency improvement: (same grade, >= 2 points improvement in CCS), 4. no improvement, or deterioration, 5. early dropouts. [ Time Frame: 9 months after randomization ]
- Use of stool regulating medication. Specifically, if biofeedback and 3T increase continence, the use of any stool regulating medication (Fleawort seeds, Loperamide, teas, etc.) should decrease in the course of the trial. [ Time Frame: 9 months after randomization ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00525291
|University of Gießen, Dept. of General Surgery|
|Gießen, Hesse, Germany, 35385|
|Principal Investigator:||Thilo Schwandner, Dr.||University of Giessen|